KURAKura Oncology, Inc.

$815M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$26M

Net Income

-$26M

EPS (Diluted)

$-0.45

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$19M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$647M

Total Liabilities

$36M

Stockholders' Equity

$611M

Cash & Equivalents

$325M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$26M	-$19M	-38.9%
Net Income	-$26M	-$18M	-46.4%

KURA Q4 2020 Earnings — Kura Oncology, Inc. Revenue & Financial Results | Market Cap Arena